Twist Bioscience Corporation $TWST Stock Sold by Voya Investment Management LLC

Voya Investment Management LLC reduced its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 19.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 539,952 shares of the company’s stock after selling 131,914 shares during the period. Voya Investment Management LLC’s holdings in Twist Bioscience were worth $104,340,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Root Financial Partners LLC purchased a new stake in Twist Bioscience in the 3rd quarter worth approximately $33,000. Signaturefd LLC raised its stake in Twist Bioscience by 94.3% during the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock worth $106,000 after acquiring an additional 266 shares during the period. Allworth Financial LP purchased a new position in Twist Bioscience during the second quarter valued at approximately $62,000. Trifecta Capital Advisors LLC purchased a new position in Twist Bioscience during the second quarter valued at approximately $63,000. Finally, Western Wealth Management LLC purchased a new position in Twist Bioscience during the first quarter valued at approximately $31,000.

Twist Bioscience Stock Up 3.9%

Shares of TWST opened at $116.35 on Thursday. The business’s 50 day moving average is $149.33 and its 200 day moving average is $94.12. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $25.23 and a 12-month high of $219.71. The company has a market capitalization of $7.30 billion, a PE ratio of -55.67 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business had revenue of $126.64 million during the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience’s revenue was up 26.7% compared to the same quarter last year. Research analysts expect that Twist Bioscience Corporation will post -1.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Leerink Partners reduced their price objective on shares of Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating for the company in a research note on Friday, November 13th. Robert W. Baird lowered their target price on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, November 13th. UBS Group initiated coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Finally, Jefferies Financial Group set a $125.00 price target on Twist Bioscience in a report on Thursday, November 12th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $133.92.

Read Our Latest Report on Twist Bioscience

Insider Activity

In related news, CEO Emily Leproust sold 4,573 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $619,184.20. Following the completion of the transaction, the chief executive officer owned 558,187 shares in the company, valued at approximately $75,578,519.80. This represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,462 shares of the company’s stock in a transaction on Friday, October 9th. The stock was sold at an average price of $156.30, for a total transaction of $384,810.60. Following the transaction, the chief financial officer owned 98,114 shares of the company’s stock, valued at approximately $15,335,218.20. This represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 495,279 shares of company stock valued at $80,489,387. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Further Reading

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.